Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
NCT ID: NCT00227305
Last Updated: 2013-01-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
381 participants
INTERVENTIONAL
2004-08-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania
NCT00090311
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
NCT00090324
Pediatric Bipolar Depression
NCT00811473
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression
NCT00083954
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
NCT00060489
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
quetiapine fumarate
Oral dosing, flexible dosing
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient previously enrolled in either double-blind Study D1441C00149 or D1441C00112
* Patient has documented clinical diagnosis of schizophrenia or bipolar I disorder
* Patient's parent or legal guardian will be able to accompany the patient to each scheduled study visit
Exclusion Criteria
* Patients with a known intolerance or lack of response to previous treatment with quetiapine
* Patients who have previously participated in this study
10 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seroquel Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Dothan, Alabama, United States
Research Site
Scottsdale, Arizona, United States
Research Site
Cerritos, California, United States
Research Site
Riverside, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
Denver, Colorado, United States
Research Site
Altamonte Springs, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Chicago, Illinois, United States
Research Site
Oak Brook, Illinois, United States
Research Site
Newton, Kansas, United States
Research Site
Overland Park, Kansas, United States
Research Site
New Orleans, Louisiana, United States
Research Site
Las Vegas, Nevada, United States
Research Site
Rochester, New York, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Lyndhurst, Ohio, United States
Research Site
Oklahoma City, Oklahoma, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Memphis, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Houston, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Richmond, Virginia, United States
Research Site
Virginia Beach, Virginia, United States
Research Site
Bellevue, Washington, United States
Research Site
Kirkland, Washington, United States
Research Site
Milwaukee, Wisconsin, United States
Research Site
Lucknow, , India
Research Site
Kuala Lumpur, , Malaysia
Research Site
Petaling Jaya, , Malaysia
Research Site
Davao City, , Philippines
Research Site
Mandaluyong, , Philippines
Research Site
Manila, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Poznan, , Poland
Research Site
Torun, , Poland
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Belgrade, , Serbia
Research Site
Novi Sad, , Serbia
Research Site
Pretoria, , South Africa
Research Site
Kharkiv, , Ukraine
Research Site
Lviv, , Ukraine
Research Site
Odesa, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Findling RL, Pathak S, Earley WR, Liu S, DelBello M. Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study. J Child Adolesc Psychopharmacol. 2013 Sep;23(7):490-501. doi: 10.1089/cap.2012.0092. Epub 2013 Sep 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1441C00150
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.